What Is CVVH and How Does the Treatment Work?

Continuous venovenous hemofiltration, usually called CVVH, is a form of kidney replacement therapy that runs around the clock in an intensive care unit, slowly filtering blood through a semipermeable membrane to remove waste products and excess fluid from critically ill patients whose kidneys have shut down. Unlike the intermittent hemodialysis sessions familiar to people with chronic kidney disease, CVVH works gently and continuously, which makes it better suited for patients who are too unstable to tolerate the rapid fluid shifts of a standard dialysis session. The treatment emerged from earlier arteriovenous techniques developed in the late 1970s and has become a mainstay of modern critical care.

How Blood Moves Through the Circuit

In CVVH, a dual-lumen catheter is placed into a large central vein, usually the internal jugular or femoral vein. Blood is drawn out through one port of the catheter by a roller pump, pushed through the filtration circuit, and returned to the body through the second port. Blood flow rates during CVVH are typically modest compared with conventional hemodialysis. In one study using a standardized setup, all patients started at a blood flow rate of 100 mL per minute, while another investigation reported flows between 120 and 170 mL per minute depending on body weight.¹² Those flow rates sound low, but the treatment runs for 24 hours or more, so total blood processing adds up considerably over time.

The heart of the circuit is the hemofilter, a cartridge packed with thousands of hollow fibers made from synthetic membranes such as polysulfone or acrylonitrile copolymer. Blood flows through the insides of those tiny tubes while a pressure gradient pushes plasma water and dissolved solutes through the membrane pores into a collection bag. This pressure-driven movement of fluid is called convection, and it is what distinguishes CVVH from dialysis-based techniques that rely primarily on diffusion across a concentration gradient.

Convection Versus Diffusion

The distinction matters because convection and diffusion clear different-sized molecules with different efficiency. Small waste products like urea and creatinine are removed well by both methods. One crossover study of critically ill patients found that time-averaged urea clearance was roughly 32 mL per minute during CVVH and 36 mL per minute during a diffusion-based mode called CVVHD, a difference that was not statistically meaningful. Creatinine clearance was similarly comparable between the two approaches.³

Where convection is thought to have an edge is with larger molecules, sometimes called middle molecules. Beta-2-microglobulin, a protein about 12,000 daltons in size, showed higher clearance during convective therapy in the same study, though the difference just missed statistical significance. The idea is that when plasma water is pushed through the membrane, it drags these bulkier molecules along with it in a process called solvent drag. Diffusion, by contrast, relies on random molecular movement down a concentration gradient, and bigger molecules move more sluggishly.

That said, membrane size and design also play a role. In vitro work has shown that when large-surface-area filters are used, convective and diffusive prescriptions can produce nearly identical middle-molecule clearance across a wide molecular-weight range. With smaller filters, high ultrafiltration rates during convective therapy can actually concentrate proteins against the membrane surface in a phenomenon called concentration polarization, creating a secondary barrier that limits clearance.⁴ So the theoretical advantage of convection is not automatic; it depends on how the treatment is set up.

Replacement Fluid and the Pre-Dilution Question

Because CVVH removes large volumes of plasma water, that fluid has to be replaced. Sterile replacement solution, balanced in electrolytes, is infused back into the blood either before or after the filter. The choice between pre-dilution and post-dilution has real practical consequences.

In post-dilution, the replacement fluid enters the circuit after the filter, so the blood passing through the membrane is undiluted. This gives you more efficient solute clearance per liter of ultrafiltrate. Research comparing the two methods found that clearance of creatinine and certain inflammatory molecules like interleukin-8 was higher during post-dilution CVVH.⁵ The tradeoff is that undiluted blood is thicker and more prone to clotting inside the filter. One study tracking hundreds of filters found that median filter life was significantly shorter with post-dilution, lasting about 13 hours compared with 18 hours for pre-dilution.⁶

Pre-dilution, where the replacement fluid is infused upstream of the filter, dilutes the blood before it hits the membrane. This keeps the filter running longer and may actually provide more stable removal of inflammatory cytokines over a full 24-hour period, which matters in septic patients. That same clearance study noted that interleukin-8 and interleukin-6 clearance declined over 24 hours during post-dilution but stayed steady during pre-dilution.⁵ In practice, many ICUs use pre-dilution as their default because a filter that lasts longer means fewer circuit changes, fewer interruptions in therapy, and less nursing workload.

Keeping the Circuit From Clotting

Blood that contacts foreign surfaces wants to clot. Every CVVH circuit is vulnerable to coagulation inside the filter fibers, and a clotted filter means the treatment stops until a new one is installed. The two main anticoagulation strategies are systemic heparin, which thins the patient’s entire bloodstream, and regional citrate anticoagulation, which works only inside the circuit.

Citrate chelates calcium, which is essential for the clotting cascade, effectively preventing coagulation inside the filter. Calcium is then infused back into the patient’s bloodstream downstream to restore normal clotting. A review of the evidence found that heparin-based anticoagulation was associated with a bleeding rate of about 13 percent, compared with roughly 2 percent for citrate-based regimens.⁷ For patients who are already at high risk of bleeding, such as those who have just come out of major surgery or have liver failure, citrate anticoagulation allows safe CVVH without worsening the bleeding risk. One study specifically looked at high-bleeding-risk patients and confirmed that citrate-based post-dilution CVVH extended filter life and reduced blood loss compared to running the circuit without any anticoagulant at all.⁸

Citrate does require careful metabolic monitoring. The liver metabolizes citrate to bicarbonate, so patients with severe liver failure can accumulate citrate, causing low ionized calcium and metabolic disturbances. Still, for most ICU patients, citrate has increasingly become the anticoagulant of choice.

Managing Fluid Removal

Waste clearance is only half the job. Many critically ill patients arrive in the ICU massively fluid-overloaded after aggressive resuscitation, and CVVH provides a way to gently pull that excess fluid off. The rate at which net fluid is removed, called the net ultrafiltration rate, is separately adjustable from the overall ultrafiltration rate used for solute clearance. Clinicians dial this in carefully, often combining intake restriction with a moderate net ultrafiltration protocol.⁹

Getting the rate right is a balancing act. Remove fluid too quickly and you risk dropping the patient’s blood pressure; remove too little and fluid overload persists, worsening lung function and organ perfusion. A multi-center study found that the median net ultrafiltration rate in practice was about 0.7 mL per kilogram per hour, and that higher rates did not appear to cause a significant immediate reduction in urine output, suggesting that reasonable fluid removal during CVVH does not obviously harm residual kidney function.¹⁰ Meanwhile, another large study found that patients managed with a net ultrafiltration rate of 35 mL per kilogram per day or higher had lower 30-day mortality than those with lower rates, with an adjusted odds ratio of 0.47, meaning roughly half the odds of death.¹¹ The relationship between fluid removal intensity and outcomes remains an active area of research, but the overall message is that resolving fluid overload matters.

Why Continuous Beats Intermittent in Unstable Patients

The primary reason CVVH and related continuous therapies are preferred in the sickest ICU patients is hemodynamic stability. Intermittent hemodialysis pulls off fluid and solutes in a three-to-four-hour session, creating rapid shifts in blood volume and osmolality that can tank blood pressure. A comparative evaluation found that patients on continuous therapy experienced only a modest decline in mean arterial pressure after treatment, while those receiving intermittent hemodialysis had a substantially greater drop in pressure along with a bigger rise in heart rate.¹²

It is worth noting that not all studies have found a dramatic hemodynamic advantage. One randomized crossover trial in ICU patients compared intermittent hemodialysis and continuous hemofiltration and found no significant difference in mean arterial pressure or vasopressor requirements.¹³ The discrepancy likely reflects differences in how aggressively each modality was prescribed. When intermittent dialysis is done cautiously with slow flow rates, the hemodynamic gap narrows. In routine ICU practice, though, continuous therapy gives the clinical team more room to adjust on the fly, and it remains the go-to option for patients on vasopressors or with unstable cardiac output.

Watching the Circuit for Trouble

CVVH machines continuously display a set of pressures that tell the bedside nurse and physician how the circuit is performing. The two most important are the transmembrane pressure, which reflects the force driving fluid through the membrane, and the filter pressure drop, which measures the resistance to blood flow across the length of the filter. Rising values in either are a warning sign that the filter is starting to clot. One pediatric study found that each 1-mmHg increase in transmembrane or filter pressure was independently associated with about a 1.5 percent higher risk of circuit clotting.¹⁴

The challenge is that both pressures are also influenced by changes in blood flow rate and ultrafiltration settings, so a pressure rise does not always mean a clot is forming. Researchers have proposed adjusted parameters that correct for these variables to reduce false alarms.¹⁵ In practice, nurses learn to read pressure trends over time rather than reacting to individual readings. A gradual upward drift in transmembrane pressure over several hours is more concerning than a brief spike after a blood-flow-rate change.

What CVVH Does to Drug Levels

One of the trickier aspects of CVVH that often surprises people outside critical care is how profoundly it affects medication dosing. The same membrane that filters waste also removes drugs from the bloodstream. How much gets pulled out depends on the drug’s molecular weight, its protein binding, and the ultrafiltration rate. Small, water-soluble drugs that are not heavily bound to plasma proteins get stripped out aggressively.

Ceftazidime, a commonly used antibiotic, is a good illustration. It has low protein binding, and studies have confirmed that its clearance is meaningfully increased by both CVVH and CVVHD regardless of which type of membrane is used.¹⁶ A case study of the newer combination ceftazidime-avibactam found that CVVH accounted for roughly 57 percent of total ceftazidime clearance and 54 percent of avibactam clearance, with high sieving coefficients near 1.0 for both drugs.¹⁷ When the filter is removing more than half of a drug’s total clearance, the usual dosing regimen for patients with kidney failure will leave them under-dosed. Getting antibiotic levels wrong in a septic ICU patient can be the difference between survival and death.

The opposite problem can also occur. Drugs that are highly protein-bound or very large pass through the membrane poorly, and if clinicians assume CVVH is clearing them, a patient could accumulate toxic levels. Cidofovir, an antiviral, had a sieving coefficient of only about 0.14 during CVVH, meaning most of the drug stayed in the bloodstream. Still, about 31 percent was removed over 24 hours, and researchers warned that toxic accumulation could occur with repeated dosing if adjustments were not made.¹⁸ Every drug used during CVVH ideally needs its own dosing adjustment, and pharmacists specializing in critical care play an essential role in calculating these.

Electrolyte Losses and Nutritional Drain

The membrane does not distinguish between waste products and useful molecules of similar size. Phosphate is a prime example. It is critical for energy metabolism in every cell, and CVVH strips it from the blood relentlessly. A study tracking phosphate balance during CVVH found that all patients remained in negative phosphate balance despite receiving protocol-driven phosphate replacement. Even on day seven of treatment, the net phosphate deficit ranged from roughly 450 to 1,260 milligrams per day.¹⁹ Since phosphate is primarily stored inside cells and is central to processes like ATP synthesis, these ongoing losses from the intracellular pool can have consequences even when serum phosphate levels look deceptively normal.

Amino acids, trace elements like zinc and selenium, and water-soluble vitamins are also lost through the membrane. Patients on prolonged CVVH often need aggressive nutritional supplementation, and standard ICU feeding protocols may not fully compensate for the drain. This is one reason clinicians try to transition patients off continuous therapy as soon as their condition stabilizes.

From Artery to Vein: How CVVH Came to Be

The ancestor of modern CVVH was continuous arteriovenous hemofiltration, or CAVH, first performed by Peter Kramer in Göttingen, Germany in 1977.²⁰ CAVH used the patient’s own blood pressure to push blood through the filter, which meant sticking a large catheter into an artery. It worked, but arterial access carried real risks of bleeding and limb injury, and the filtration rate was limited by whatever arterial pressure the patient could generate. In hypotensive patients, the very people who needed continuous therapy most, CAVH sometimes could not produce adequate clearance.²¹

The solution was to replace the arterial catheter with a venous one and add a blood pump to drive flow. This pump-driven venovenous approach eliminated the dependence on the patient’s own circulation and allowed clinicians to control blood flow precisely.²² The result, CVVH, rapidly supplanted CAVH through the 1990s and remains the dominant hemofiltration technique in critical care today.

Renal Recovery After CVVH

A question that weighs on patients and families is whether the kidneys will recover once the acute crisis passes. The good news is that for many survivors, they do. In one cohort of critically ill COVID-19 patients who required renal replacement therapy, kidney function recovered to a mild impairment level in about 64 percent of those with acute kidney injury by the time they left the ICU.²³ Longer-term data tell a more sobering story, however. A study following CRRT survivors over five years found one-year survival around 64 percent, three-year survival near 56 percent, and five-year survival about 46 percent. The factors most strongly associated with worse long-term outcomes included older age, sepsis, pre-existing kidney disease, and poor kidney function at hospital discharge.²⁴

It is important to separate the prognosis of the kidney injury itself from the prognosis of the patient. Many of the deaths in these studies are driven by the underlying diseases that caused kidney failure in the first place, not by the CVVH treatment. A patient who develops acute kidney injury after a massive heart attack faces different long-term odds than one whose kidneys shut down from a reversible drug reaction, even if both received the same therapy.

The Cost Question

CVVH is resource-intensive. It requires specialized machines, disposable circuits and filters, replacement fluid bags, anticoagulation supplies, and dedicated nursing attention around the clock. One cost analysis estimated weekly hospital costs of roughly $2,600 for continuous therapy with heparin anticoagulation and about $3,100 with citrate, compared with approximately $1,400 for sustained low-efficiency dialysis, a hybrid alternative that runs for longer sessions on a conventional dialysis machine.²⁵ A randomized trial confirmed that the hybrid approach also required less nursing time.²⁶

These costs are partly why CVVH is not used for every ICU patient with kidney failure. When a patient is hemodynamically stable enough to tolerate intermittent or hybrid dialysis, there is no proven survival benefit to continuous therapy, and the cheaper option is perfectly reasonable. CVVH earns its keep in the patients who genuinely cannot tolerate alternatives: those on high-dose vasopressors, with severe fluid overload, with brain injuries where rapid osmolar shifts could be dangerous, or with multi-organ failure requiring precise moment-to-moment fluid management.

Cytokine Removal in Sepsis

Beyond waste and fluid clearance, CVVH has drawn interest for its ability to remove inflammatory mediators from the blood during sepsis. Cytokines like interleukin-6, interleukin-8, and tumor necrosis factor are middle-sized molecules that fall within the clearance range of high-flux membranes. Research using AN69 membranes showed that increasing the blood flow rate from 100 to 200 mL per minute boosted the ultrafiltration rate by about 75 percent and significantly increased both convective removal and membrane adsorption of cytokines.²⁷ Frequent membrane changes also helped, because adsorption capacity saturates over time as binding sites on the membrane fill up.

Whether removing cytokines from the bloodstream actually improves outcomes in sepsis remains an unresolved question. The blood concentrations of these mediators are a tiny fraction of what is present in tissues, and the body produces them continuously during active infection. Pulling some out of the bloodstream may be akin to bailing a boat with a teaspoon. Still, the concept has fueled development of specialized high-adsorption membranes and high-volume hemofiltration protocols aimed at modulating the inflammatory response, and clinical trials continue to explore whether any of these approaches translate into survival gains.